Filing Overview
This Form 6-K was filed January 10, 2020 by Happiness Biotech Group Limited, not Paranovus Entertainment Technology Ltd. The filing reports unaudited results for the six months ended September 30, 2019, compared with the six months ended September 30, 2018. The business manufactures and sells nutraceutical and dietary supplements in China, including products based on Lucidum spore powder, Cordyceps mycelia, Ejiao, vitamins, dietary supplements, and American ginseng.
Key Financial Metrics
| Metric | Six months ended September 30, 2019 | Comparable period |
|---|---|---|
| Revenue | $31.36 million | $31.43 million |
| Gross profit | $15.83 million | $15.85 million |
| Gross margin | 50.5% | 50.4% |
| Operating income | $9.82 million | $10.38 million |
| Net income | $8.42 million | $8.80 million |
| Net margin | 26.9% | 28.0% |
| Net cash provided by operations | $8.94 million | $5.10 million |
| Basic and diluted EPS | $0.37 | $0.38 |
As of September 30, 2019, cash and cash equivalents were $23.83 million, current assets were $59.50 million, and current liabilities were $5.08 million. Short-term bank borrowings were $2.04 million. No commitments or contingencies were reported in the balance sheet. Total assets were $71.32 million and shareholders’ equity was $66.24 million.
Material Changes Versus Prior Period
- Revenue decreased $75,658, or 0.2%, with growth in Lucidum spore powder products largely offset by declines in Cordyceps, Ejiao, vitamins and dietary supplements, and American ginseng products.
- Lucidum spore powder revenue increased 18.3% to $10.95 million, attributed to increased marketing and experience-store sales.
- Cordyceps mycelia revenue declined 18.3% to $4.70 million, primarily due to increased competition and lower retail prices.
- Gross profit was essentially unchanged, while operating expenses increased 9.9% to $6.00 million. Selling and marketing expense rose 8.2%, and general and administrative expense rose 31.5%.
- Operating income declined 5.4% and net income declined 4.3%. Other income improved from a net expense of $24,366 to net income of $82,207.
- Foreign currency translation loss improved from $4.17 million to $3.10 million, but comprehensive income was $5.32 million versus $4.64 million in the prior period.
- Cash increased from $14.80 million at March 31, 2019 to $23.83 million at September 30, 2019, while current liabilities increased from $4.76 million to $5.08 million.
IPO, Outlook, Risks and Unusual Items
On October 25, 2019, the company closed an initial public offering of 2,000,000 ordinary shares at $5.50 per share. Gross proceeds were $11.00 million and net proceeds were $10.01 million after underwriting discounts, commissions, and offering expenses.
The filing provides no quantitative financial guidance or specific operating outlook. Management cited intensified competition and pricing pressure in traditional nutrition markets, increased brand advertising costs, and growth from newly promoted Lucidum-enriched products. The company reported approximately 32 products with “Blue Caps” approval, more than 200 distributors across 27 provinces, and 30 experience stores in China as of September 30, 2019.
The financial statements are unaudited and may be materially adjusted during year-end audit work. The filing also includes customary forward-looking statement risks, including uncertainty that actual performance may differ materially from expectations. Foreign currency translation losses are a notable non-operating item.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Happiness Biotech Group Limited, whereas the request metadata names Paranovus Entertainment Technology Ltd.
- Confirm the final audited results and any adjustments to the unaudited September 30, 2019 figures.
- Assess the use of the IPO’s $10.01 million net proceeds and the terms and maturity of the $2.04 million in short-term bank borrowings.
- Evaluate whether Lucidum product growth can offset continuing competition and pricing pressure affecting other product categories.
- Review foreign exchange exposure and the impact of translation adjustments on reported comprehensive income.